Sofiva Genomics Co.,Ltd. (TPEX:6615)
Taiwan · Delayed Price · Currency is TWD 34.05
-0.30 (-0.87%)
At close: Feb 11, 2026
Sofiva Genomics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 393.48 | 453.31 | 466.8 | 495.78 | 508.42 | 488.87 | |
Revenue Growth (YoY) | -15.32% | -2.89% | -5.85% | -2.49% | 4.00% | -4.04% |
Cost of Revenue | 289.91 | 317.65 | 336.89 | 346.79 | 331.6 | 336.12 |
Gross Profit | 103.58 | 135.66 | 129.91 | 148.99 | 176.81 | 152.74 |
Selling, General & Admin | 125.27 | 129.06 | 136.15 | 135.35 | 130.91 | 122.54 |
Research & Development | 11.2 | 9.98 | 9.64 | 10.34 | 10.8 | 9.62 |
Operating Expenses | 136.46 | 139.03 | 145.79 | 145.2 | 141.57 | 131.82 |
Operating Income | -32.89 | -3.37 | -15.88 | 3.79 | 35.24 | 20.92 |
Interest Expense | -0.94 | -1.11 | -1.29 | -1.49 | -1.74 | -1.97 |
Interest & Investment Income | 1.41 | 1.4 | 1.46 | 0.67 | 0.35 | 0.41 |
Earnings From Equity Investments | 25.05 | 25.35 | 23.67 | 41.9 | 31.05 | 17.5 |
Currency Exchange Gain (Loss) | -1.26 | - | - | - | - | - |
Other Non Operating Income (Expenses) | 2.28 | 1.35 | 0.95 | 2.48 | -1.2 | 0.41 |
EBT Excluding Unusual Items | -6.34 | 23.62 | 8.9 | 47.35 | 63.69 | 37.28 |
Pretax Income | -6.34 | 23.62 | 8.9 | 47.35 | 63.69 | 37.28 |
Income Tax Expense | 3.31 | 4.49 | -3.02 | 4.2 | 6.92 | 3.07 |
Earnings From Continuing Operations | -9.65 | 19.13 | 11.92 | 43.15 | 56.77 | 34.21 |
Minority Interest in Earnings | -0.54 | -0.7 | -0.4 | -0.38 | 0.21 | 0.41 |
Net Income | -10.18 | 18.43 | 11.53 | 42.78 | 56.98 | 34.62 |
Net Income to Common | -10.18 | 18.43 | 11.53 | 42.78 | 56.98 | 34.62 |
Net Income Growth | - | 59.88% | -73.05% | -24.92% | 64.58% | -44.76% |
Shares Outstanding (Basic) | 22 | 21 | 21 | 21 | 21 | 21 |
Shares Outstanding (Diluted) | 22 | 22 | 21 | 21 | 21 | 21 |
Shares Change (YoY) | 0.04% | 1.28% | -0.04% | 0.40% | -0.43% | -0.34% |
EPS (Basic) | -0.47 | 0.86 | 0.54 | 2.00 | 2.68 | 1.63 |
EPS (Diluted) | -0.47 | 0.85 | 0.54 | 2.00 | 2.68 | 1.62 |
EPS Growth | - | 57.52% | -73.02% | -25.30% | 65.26% | -44.52% |
Free Cash Flow | 10.95 | 17.77 | 2.69 | -16.4 | 71.91 | 45.35 |
Free Cash Flow Per Share | 0.51 | 0.82 | 0.13 | -0.77 | 3.38 | 2.12 |
Dividend Per Share | 0.300 | 0.300 | 0.200 | 1.000 | 2.000 | 1.400 |
Dividend Growth | 50.00% | 50.00% | -80.00% | -50.00% | 42.86% | -46.15% |
Gross Margin | 26.32% | 29.93% | 27.83% | 30.05% | 34.78% | 31.24% |
Operating Margin | -8.36% | -0.74% | -3.40% | 0.76% | 6.93% | 4.28% |
Profit Margin | -2.59% | 4.07% | 2.47% | 8.63% | 11.21% | 7.08% |
Free Cash Flow Margin | 2.78% | 3.92% | 0.58% | -3.31% | 14.14% | 9.28% |
EBITDA | -6.2 | 22.46 | 10.21 | 29.85 | 60.4 | 52.19 |
EBITDA Margin | -1.57% | 4.96% | 2.19% | 6.02% | 11.88% | 10.67% |
D&A For EBITDA | 26.69 | 25.83 | 26.1 | 26.06 | 25.16 | 31.26 |
EBIT | -32.89 | -3.37 | -15.88 | 3.79 | 35.24 | 20.92 |
EBIT Margin | -8.36% | -0.74% | -3.40% | 0.76% | 6.93% | 4.28% |
Effective Tax Rate | - | 19.00% | - | 8.86% | 10.87% | 8.24% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.